JLE

Epileptic Disorders

MENU

Adjunctive lacosamide for focal epilepsy: an open-label trial evaluating the impact of flexible titration and dosing on safety and seizure outcomes Volume 19, issue 2, June 2017

Figures


  • Figure 1

  • Figure 2

Tables

Authors
1 IHU-ICM and Department of Neurology, Pitié-Salpêtrière Hospital, Paris
2 UCB Pharma, Colombes, France
3 UCB Pharma, Raleigh, USA
4 UCB Pharma, Brussels, Belgium
5 Neurophysiology Clinic, University Hospital La Timone (AP-HM), Marseille
6 IHU-ICM and Department of Neurosurgery, Pitié-Salpêtrière Hospital, Paris, France
* Correspondence: Michel Baulac Clinique Neurologique, Hôpital de la Pitié-Salpêtrière, 47-83 Boulevard de l’Hôpital, Paris 75013, France

Aims

To evaluate the safety and effectiveness of lacosamide in a real-life setting with the use of a flexible dose titration schedule and individualised maintenance doses up to the maximum approved dose of 400 mg/day.